GSK RSV vaccine Arexvy accepted for review in China for adults over 60
(Alliance News) - GSK PLC on Tuesday said its respiratory syncytial virus vaccine Arexvy has been accepted for review by China's Center for Drug Evaluation for adults aged 60 and over. Read More